Transaction · 0002064832-26-000316

Lantheus Holdings, Inc.

Lantheus Holdings, Inc., 10% Owner, reported an open-market or private sale at Perspective Therapeutics, Inc. involving 42129.000000 shares for an estimated $131219.20. Reported holdings after the transaction were 11521296.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

Open-market sellSEC transaction code S10%
CATXPerspective Therapeutics, Inc.
Filing timeSep 04
Trade dateSep 02, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$3.13
Pre-filing
1mo ago1w ago1d ago
Returns since
7d +0.0%30d +0.0%90d +0.0%180d +0.0%1y +0.0%

CATX price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CATX since 2026-09-04Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0002064832-26-000316
Common Stock
Transaction date
Sep 02, 2026
Filed Sep 04, 2026, 09:00 PM · 2d delay
Shares
42.1k sh
$311 per share
Estimated value
-$13.1M
Computed from shares × price
Holdings after
11.5M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Cluster Selling Direct Ownership Repeat Seller
+10score
Filing-only score

+10

Compact filing score computed from stored Form 4 facts. Version v1.

Positive filing signal

This filing has a modest positive filing-only score. Treat it as a useful flag for review, not as a buy signal.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

No officer title

Officer NoDirector No10% YesOther No
Footnotes & amended
  1. F1

    The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.025 to $3.235, inclusive. The reporting person undertakes to provi…

  2. F2

    Represents securities directly held by Lantheus Alpha Therapy, LLC ("Lantheus"), a wholly owned indirect subsidiary of Lantheus Holdings, Inc. ("Lantheus Holdings"). Under SEC rules and regulations, L…

Original filing · 0002064832-26-000316
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CATX